However, some studies demonstrated that anlotinib directly inhibited tumor cells rather than angiogenesis [15,22,27,28,29], and an increasing number of unconventional pharmacologic targets have been identified [15,22,30,31], such as EGFR and c-Myc. This evidence concerns the gene MYC and neoplasm.